Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077317 | 0.84 | TSHR (0.37) | TSHRHCRTR2PAX8CYP2D6SMN1; SMN2 | |
| SCHEMBL20620962 | 0.83 | CA1 (0.31) | — | |
| SCHEMBL22200880 | 0.75 | KDM4E (0.39) | TSHRPAX8JAK1MEN1KMT2A | |
| SCHEMBL10217000 | 0.74 | ALDH1A1 (0.47) | CYP2D6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22870070 | 0.73 | TP53 (0.34) | TSHRPAX8JAK1SMN1; SMN2 | |
| SCHEMBL22870065 | 0.73 | TP53 (0.34) | TSHRPAX8JAK1SMN1; SMN2 | |
| SCHEMBL10232851 | 0.72 | TSHR (0.44) | TSHRHCRTR2CYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL12384515 | 0.72 | TSHR (0.44) | TSHRHCRTR2CYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL13368879 | 0.72 | TSHR (0.44) | TSHRHCRTR2CYP2D6SMN1; SMN2MEN1 | |
| SCHEMBL23784262 | 0.72 | OPRL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | TSHR 2373/4885HCRTR2 1040/4885PAX8 3250/4885 |
| US-20190055219-A1 | INDOLE DERIVATIVES AND USES THEREOF | MYLK2, MYOF, MUSK | TSHR 2411/4885HCRTR2 2831/4885PAX8 451/4885 |
| US-10654828-B2 | Indole derivatives and uses thereof | MYLK2, MYOF, MUSK | TSHR 2411/4885HCRTR2 2831/4885PAX8 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.